British biotech company, PetScreen Limited has developed an innovative screening and treatment optimisation programme for canine lymphomalinks, which accoutns for 20% of cancers in high-risk breeds. This is the first of its kind to be made commercially available.
PetScreen has developed the screen based on proteomic technology which has emerged from the sequencing of both the human and canine genomes. It facilitates regular, routine screening which enables cancer to be detected at a much earlier stage when, as in humans, treatment has the best chance of success.
According to the Pet Screen’s press release, one in four dogs develop cancer in their lifetimes and recommend that the screen be regarded as part of pet’s overall wellness programme.
Well, if your pet insurance provider would cover it, why not?